For an elderly dementia patient receiving memantine, donepezil, high‑dose amisulpride, levodopa, and trihexyphenidyl, how should the antipsychotic, levodopa, and anticholinergic be tapered or stopped, and what safer alternative treatments are recommended for behavioral symptoms and urinary incontinence?

Immediate Priority: Stop Trihexyphenidyl and Taper Amisulpride

The trihexyphenidyl (3mg) must be discontinued immediately as anticholinergics are contraindicated in dementia and directly worsen cognition, while the high-dose amisulpride (400mg) should be gradually tapered given the lack of evidence for benefit and significant mortality risk in elderly dementia patients. The levodopa 600mg is also inappropriate unless there is documented Parkinson's disease dementia, and should be reduced or stopped. The memantine-donepezil combination can be continued if there has been documented benefit.

Critical Medication Issues

1. Trihexyphenidyl - STOP IMMEDIATELY

• Anticholinergics are absolutely contraindicated in dementia - they directly antagonize the cholinesterase inhibitor (donepezil) and independently worsen cognition 1
• Anticholinergics should be avoided in dementia wherever possible as they negate the effects of cognitive enhancers and have direct adverse effects on cognition 1
• The "improvement" in incontinence is likely due to anticholinergic urinary retention, not true improvement
• Taper schedule: Reduce by 1mg every 3-4 days (total discontinuation over 9-12 days)

2. Amisulpride 400mg - TAPER AND DISCONTINUE

Antipsychotics should only be used when symptoms are severe, dangerous, or cause significant distress 2. The 2016 APA guidelines are clear:

• Antipsychotics carry significant mortality risk (stroke, cardiovascular events, death) in elderly dementia patients 2, 3
• They should be reserved for acute-onset severe behavioral symptoms or when patients pose danger to themselves/others 2
• If behavioral symptoms have been stable and the patient is not acutely dangerous, the antipsychotic should be tapered 2

Tapering protocol for amisulpride:

• Reduce by 25% every 2 weeks: 400mg → 300mg → 200mg → 100mg → 50mg → stop
• Monitor closely for behavioral deterioration during taper
• If severe agitation/aggression re-emerges, consider lower maintenance dose (50-100mg) rather than 400mg

3. Levodopa 600mg - ASSESS INDICATION

Critical question: Does this patient have documented Parkinson's disease dementia (PDD)?

• If NO PDD diagnosis: Taper and discontinue levodopa as it has no role in Alzheimer's dementia and may worsen behavioral symptoms

  • Reduce by 100mg every week: 600mg → 500mg → 400mg → 300mg → 200mg → 100mg → stop

• If PDD is documented: The memantine-donepezil combination is appropriate 4, but 600mg levodopa is high

  • Consider reducing to 300-400mg daily if motor symptoms allow
  • Balance motor benefit against potential psychiatric side effects

4. Memantine + Donepezil - CONTINUE IF BENEFICIAL

Do NOT discontinue the cholinesterase inhibitor while behavioral symptoms are present 4. The 2020 Canadian guidelines specifically state: "Cholinesterase inhibitors should not be discontinued in individuals who currently have clinically meaningful psychotic symptoms, agitation, or aggression until these symptoms have stabilized" 4

• The combination is appropriate for moderate-to-severe dementia 5
• Recent evidence shows combined memantine-donepezil increases 5-year survival by 6.4% compared to no treatment 5
• Continue current doses unless there are intolerable side effects

Better Alternatives for Behavioral Symptoms

Non-Pharmacological Interventions (FIRST-LINE)

Before any medication changes, implement:

• Environmental modifications to reduce agitation triggers
• Structured daily routines
• Caregiver education on behavioral management techniques
• Address pain, constipation, urinary retention, or infection as triggers

Pharmacological Alternatives if Needed

For agitation/behavioral symptoms:

• Citalopram 10-20mg daily - conditionally recommended for agitation in Alzheimer's disease 6
• Consider only if non-pharmacological approaches fail and symptoms remain severe

For psychosis (if present):

• If antipsychotic is truly necessary after taper attempt, use lowest effective dose
• Risperidone 0.25-1mg daily (not 400mg amisulpride equivalent) 6
• Reassess need every 4 weeks 2

For Urinary Incontinence

The "improvement" with trihexyphenidyl is urinary retention, not continence:

• Scheduled toileting every 2-3 hours
• Pelvic floor exercises if feasible
• Avoid bladder irritants (caffeine, alcohol)
• Consider prompted voiding protocols
• Do NOT use anticholinergics - they worsen cognition and create false improvement through retention

Implementation Algorithm

Week 1-2:

1. Stop trihexyphenidyl immediately (taper over 9-12 days)
2. Begin amisulpride taper (400mg → 300mg)
3. Continue memantine-donepezil unchanged

Week 3-4:

1. Continue amisulpride taper (300mg → 200mg)
2. Assess for behavioral changes
3. Implement non-pharmacological interventions

Week 5-6:

1. Continue amisulpride taper (200mg → 100mg)
2. Begin levodopa assessment/taper if no PDD indication

Week 7-8:

1. Complete amisulpride discontinuation (100mg → 50mg → stop)
2. Monitor for 4 weeks off antipsychotic

Week 9-12:

1. If behavioral symptoms re-emerge and are severe/dangerous, consider citalopram 10mg or low-dose risperidone (0.5mg)
2. Complete levodopa taper if indicated

Critical Pitfalls to Avoid

• Never abruptly stop antipsychotics - risk of withdrawal and rebound agitation
• Never continue anticholinergics in dementia - they are contraindicated 1
• Do not stop donepezil during active behavioral symptoms 4
• Do not attribute urinary retention to "improvement" - this is an adverse effect masquerading as benefit
• Do not restart high-dose antipsychotics - if symptoms recur, use lowest effective dose and reassess frequently 2

The perceived "improvement" is likely from anticholinergic-induced urinary retention and sedation from excessive antipsychotic dosing, not true therapeutic benefit. This polypharmacy regimen is causing more harm than good and requires systematic deprescribing.